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A B S T R A C T
Background: Cancer patients are at high risks of manifesting drug–drug interactions (DDIs) which can
potentiate serious negative outcomes. It is important for clinicians to make accurate, timely, safe and
effective decisions with regards to drug use in the patient.
Objective: To provide clinicians with an oncology-speciﬁc drug interaction database that is relevant to
their daily practice. This database focuses on DDIs with anticancer drugs (ACDs), single- and multiple-
agent chemotherapy regimens.
Methods: Drug-related and interaction-related information between anticancer and antiepileptic drugs
were compiled from drug information handbooks and databases, package inserts, and published
literature from PubMed. Web documents were served from a modiﬁed web server with a database
engine and programming interface constructed using Adobe software and various programming scripts.
Results: OncoRx is an oncology-speciﬁc database whose structure is designed around chemotherapy
regimens and generic drug names used in anticancer treatment. OncoRx currently comprises of 117
ACDs and 256 single-agent and combination chemotherapy regimens. It covers all the major classes of
ACDs and their frequently prescribed chemotherapy regimens, and can detect up to over 2000
interactions with 24 antiepileptic drugs. Data provided to clinicians include pharmacokinetic
parameters of the drugs, information regarding the chemotherapy regimens and the detected DDIs.
Conclusion: OncoRx is able to identify DDIs between ACDs and adjuvant drug therapy. This is the ﬁrst
database of its kind to be able to detect interactions for combination chemotherapy regimens. This tool
will assist clinicians in improving clinical response and reducing adverse effects based on the therapeutic
and toxicity proﬁles of the drugs.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Anticancer therapy generally consists of either single-drug or
multiple-drugs regimen. The increasing knowledge of cell kinetics
and the pharmacology of anti-tumor agents has led to their
combined use so as to maximize therapeutic outcomes.1 Newer
drugs, such as the targeted therapies, are gaining widespread
interests due to their roles in the treatment of various cancers,2–5
and are also considerably being used in combination with ﬁrst-line
cytotoxic chemotherapies.6 However, this increase in the use of
combination therapies in cancer patients poses them to high risks of
manifesting drug–drug interactions (DDIs). DDIs are thought to be* Corresponding author at: Department of Pharmacy, Faculty of Science, National
University of Singapore, Block S4, 18 Science Drive 4, Singapore 117543, Singapore.
Tel.: +65 6516 7814; fax: +65 6779 1554.
E-mail addresses: yapkevin@ymail.com (K.Y.-L. Yap), phaac@nus.edu.sg
(A. Chan).
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doi:10.1016/j.seizure.2009.11.004the cause of approximately 20–30% of all adverse drug reactions,7
and the risk of DDIs has been found to increase markedly from 5.6%
to 84% when the number of concomitant medications is increased
from 2 to 6.8 This is because anticancer drugs (ACDs) not only have
complex pharmacological proﬁles, but also narrow therapeutic
indices and steep dose–toxicity curves. In addition, physiological
changes which occur in cancer patients predispose them to high
incidencesofDDI-relatedadverse events. A recent studymanaged to
identify at least one potential drug interaction in 27% of cancer
patients,with86% classiﬁedasbeingofmajor ormoderate severity.9
As an example, the interaction between ﬂuorouracil (an ACD) and
phenytoin, an antiepileptic drug (AED), can cause increased plasma
concentrations of phenytoin due to decreased metabolism, leading
to signs and symptomsof phenytoin toxicity (e.g. unsteady gait).10 A
failure to recognize these harmful DDIs may give rise to negative
outcomes in patients.
Seizures are commonly seen in patients who present with brain
tumors and metastases. The incidence can range from 20% to 70%
depending on their tumor type.11 A further 10–20% of patients arevier Ltd. All rights reserved.
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often increases in frequency and severity.11 In addition, central
nervous system (CNS) metastasis is also a major concern to a
number of primary cancers. The number of cases of each primary
cancer type that may manifest CNS metastasis can vary.12
Symptomatically, many of these patients with CNS metastasis
may experience seizure episodes and need long-term anticonvul-
sant therapy. The efﬁcacy of AEDs in the treatment of epilepsy is
well-established,13,14 and the prophylactic use of anticonvulsant
therapy is common practice for clinicians treating patients with
brain tumors,15 regardless whether these patients have had
episodes of seizures in the past, presumably based on personal
preference, training and experience, despite a lack of clinically
available evidence on its efﬁcacy. The liability issue of being
‘‘sensitive’’ to any untoward results of the patient, such as seizures,
leading to unnecessary legal action by family members may also
bias this practice.16
Thus, it is important for clinicians tomake accurate, timely, safe
and effective decisions with regards to drug use in the patient.
They must be vigilant when prescribing other concomitant
medications with anticancer agents so as to prevent unwanted
toxicities and inadequate drug exposures due to DDIs. There are
three scenarios in which DDIs can potentially affect the therapy for
cancer patients: (a) addition of an interacting drug to a patient’s
existing chemotherapy treatment, (b) giving chemotherapy
treatment to a patient who is concurrently on an interacting drug,
and (c) removal of an interacting drug from a patient’s chronic
chemotherapy. Pharmacokinetic and/or pharmacodynamic inter-
actions can result, leading to clinically signiﬁcant toxicities or
therapeutic failures.7 By knowing the magnitude of the DDIs,
clinicians can better manage their patients’ drug therapies.
Information technology (IT) has gained increasing acceptance
among healthcare professionals in their clinical practice. The
application of cancer informatics has enabled healthcare profes-Fig. 1. Flowchart showing the processsionals to keep themselves updated in the latest developments in
oncology, and also proper therapeutic management strategies
through the use of online databases and software tools.17 Drug
information databases which provide relevant DDI information on
ACD therapies can potentially improve pharmaceutical care in
cancer patients and improve their quality of life. Although there are
more than 2000 drug interactions that have been identiﬁed, only a
limited number are of interest from a clinical standpoint.18 The
challenge is for the healthcare professional to critically evaluate
the vast amounts of available information so as to provide the best
care for the patient’s well-being.
Multiple online databases are available as drug information
resources to healthcare professionals, such as the American
Hospital Formulary Service (AHFS) Drug Information,19 British
National Formulary (BNF),20 Lexi-Comp Online21 and Micromedex
Healthcare Series.22 However, currently no drug interaction
database is dedicated to allow the search of ACD interactions by
chemotherapy regimens. Most of the currently available drug
interaction databases require the input of individual drugs in a
patient’s prescription in order to search for drug interactions. Thus,
the objective of this project is to provide clinicians dealing with
cancer patients with an oncology-speciﬁc drug interaction
database that is relevant to their daily practice. This database
will focus on DDIs with ACDs, single- and multiple-agent
chemotherapy regimens.
2. Materials and methods
The development of OncoRx involves three main steps: (a) the
compilation of information on drugs, chemotherapy regimens and
drug interactions from published literature sources, (b) the
creation of the database and graphical user interface, and (c) the
mounting of the database onto the server. A summary illustrating
the process of developing OncoRx is shown in Fig. 1.of creating the OncoRx database.
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and drug interactions
Drug information on ACDs and AEDs were collated from the
British National Formulary (53rd ed.),23 Lexi-Comp’s Drug
Information Handbook (15th ed.)24 and Drug Information Hand-
book for Oncology (6th ed.),25 the BC Cancer Agency (BCCA) Cancer
Drug Manual,26 DrugBank27 and PharmGKB databases,28 Micro-
medex1Healthcare Series (v5.1),29 and product information of the
various drugs. In addition, chemotherapy regimens that are
positively evaluated in Phase II or III trials and published in
English-language journals, or regimens which are approved by the
US FDA, were collated from PubMed using the keywords
‘‘chemotherapy regimens’’, ‘‘anticancer drugs’’ and the generic
names of the ACDs. These regimens included both single- and
multiple-agent combinations. Each individual drug used in the
chemotherapy regimen was then listed out so that its interaction
with AEDs could be compiled. In each case, references in scientiﬁc
literature describing the regimenwould also be collated. However,
since the treatment combinations can vary among different
institutions in terms of doses and frequencies of administration,
these parameters were not included in our database.
Drug-related information compiled included the generic names
and indexed terms of the drugs, their pharmacological categories,
mechanisms of action, percentages of bound protein, metabolism
and elimination routes, and enzymatic parameters; while chemo-
therapy-related information included the acronyms of the
chemotherapy regimens, the drugs used in the regimen, the types
of cancer they treat, and references substantiating the use of the
regimens in cancer treatment.
On the other hand, drug interaction information consisted of
the interaction effects, interaction mechanisms, substantiating
evidences, proposed management plans, and references. These
information were compiled from the resources previously
mentioned, as well as documented literature from PubMed basedFig. 2. Graphical user interface of OncoRx. Users can search for drug interactions basedon the keywords ‘anticancer’, ‘antiepileptic’, ‘chemotherapy
regimen’, ‘drug interactions’, and the generic names of the
individual ACDs and AEDs. When the DDI documented in the
various resources was found to be different, this information
would be collated together with the appropriate substantiating
evidence and reference citations.
2.2. Creation of the database and graphical user interface
The data collected was distributed into interrelated tables in
Microsoft Excel. The program structure of the search interface was
designed around the generic names of the ACDs, as well as
combination chemotherapy regimens. A Structured Query Lan-
guage (SQL), known as MySQL, was then used to create tables and
store data information in a MySQL 5.0 database based on the
structure of the excel tables. Documents were created using the
Adobe Dreamweaver CS4 software, and were associated with a
combination of hypertext markup languages (HTML) and java-
scripts. Cascading style sheets (CSS) were used in the designing of
theweb documents so as to provide a consistent look for thewhole
website.
2.3. Mounting of the database onto the server
The OncoRx database was programmed with a server-side
scripting language known as hypertext preprocessor (PHP 5)
running as a common gateway interface (CGI) application. A
domain was bought from the DreamHostTM web hosting compa-
ny,30 which used an Apache 2.0 web server installed on a Debian
Linux server. An open source tool written in PHP, known as
phpMyAdmin 2.11.2.1, was used to handle MySQL administration
over theweb. PHP is a scripting language designed to be embedded
in HTML, and a CGI enables the client web browser to request data
from the web server. Database queries were handled through SQL
access to the database, and the contents of the database wereon generic names of the anticancer drugs or combination chemotherapy regimens.
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somewhat arbitrary with other languages such as Active Server
Pages (ASP) and Perl being themore popular ones. However, PHP is
gaining recognition due to its ease of implementation, thus it was
used in this project.
3. Results
3.1. OncoRx—a database for detecting drug interactions with
chemotherapy regimens
OncoRx is an online oncology database whose structure is
designed around chemotherapy regimens and generic drug names
used in anticancer treatment. The database can be accessed at the
web link www.onco-informatics.com. The ﬁrst module concen-
trates on interactions of single- and multiple-agent chemotherapy
regimens with AEDs. Users can search for a drug interaction from 2
search interfaces—using either generic drug names of the ACDs or
chemotherapy combination regimens (Fig. 2).
The OncoRx database currently consists of 117 ACDs which
make up 256 single-agent and combination chemotherapy regi-
mens, and can detect up to over 2000 interactions with 24 AEDs.
The database covers all the major classes of ACDs and their
frequently prescribed chemotherapy combination regimens used
in the treatment of cancer patients. It focuses primarily on
pharmacokinetic-related DDIs since majority of the interactions
are known to involve the induction and/or inhibition of hepatic
cytochrome P450 (CYP450) metabolism. The AEDs in the database
include the commonly used older generation drugs such as
carbamazepine, phenytoin, phenobarbital, primidone and valproic
acid, as well as the newer generation drugs like gabapentin,
lamotrigine and levetiracetam.
3.2. Search strategy for interactions using generic anticancer
drug names
Users can search for a DDI by the generic name of the ACD, for
example between doxorubicin and valproic acid, using the scroll-
down menu as shown in Fig. 3. The relevant data will be extracted
from the database and the results displayed for the user. The
information is presented in tabular format and consists of three
parts: the pharmacokinetic parameters of the ACD and AED, and
parameters of the detected DDI.
The generic names of the user choice of ACD and AED are
displayed at the top of the results page, togetherwith other indexed
terms of the drugs. Pharmacokinetic data include the absorption,
protein-binding information, metabolism and elimination routes of
the drugs, as well as enzymatic parameters such as substrate,
inducer and/or inhibitor information. In addition, the pharmacolog-
ical category of the ACD, its indication in cancer therapy, and
mechanism of action are also shown to users. The last section of the
results page provides the interaction effects, mechanism and a
summary of the studies that substantiate the DDI, together with a
proposed management plan for the DDI. In the given example, a
decrease in plasma valproic acid levels is expected, which may lead
to decreased effectiveness of the AED and possible loss of seizure
control.31 The clinician should monitor the patient for seizure
control when using these two drugs concurrently, or consider an
alternative antiepileptic. Other AEDs in which an interaction with
the ACD is not identiﬁed are listed as well.
3.3. Search strategy for interactions using the acronyms of
chemotherapy regimens
Clinicians can also search for interactions of a combination
chemotherapy regimen with an AED based on the acronym of theregimen, such as EP and phenytoin (Fig. 4). EP is a combination
chemotherapy regimen consisting of etoposide and cisplatin, and
used for the treatment of small-cell lung cancer.32 As shown in the
results, this time, in addition to the pharmacokinetics of each ACD
in the regimen and the AED, information on the chemotherapy
regimenwill be shown. These include the types of cancers which it
is indicated for, the drugs in the regimen, as well as relevant
substantiating references. The management plan proposed for the
detected DDI, however, is now for the combination regimen
instead of the individual ACDs. With regards to EP, the results
caution the clinician to monitor for adequate patient response to
etoposide, plasma phenytoin levels, as well as seizure control.
3.4. Other features of OncoRx
This database caters towards health professionals who special-
ize in oncology and neurology, as well as those in general
disciplines who encounter cancer patients in their daily practice.
Besides enabling DDI searches based on chemotherapy regimen
acronyms, an additional feature was also incorporated so that
clinicians can search for DDIs of chemotherapy regimens based on
various types of cancers. This makes it easier for clinicians to
search for a particular regimen if they know the type of cancer
which the patient is suffering from. Currently, the regimens in
OncoRx have been classiﬁed into 16 categories which range from
bone and tissue cancers to HIV-related cancers and pediatric
regimens (Fig. 5). Akin to other medical disciplines, oncology
practitioners have their own clinical specializations. For example,
an oncologist can specialize in treating breast and gynecologic
cancers, while another’s expertise may lie in the treatment of
gastrointestinal and colorectal cancers. In such cases, users can
search for DDIs of speciﬁc chemotherapy regimens based on the
type of tumors or malignancies which they treat. Needless to say,
cancers affecting the CNS and brain would be of great relevance to
neuro-oncologists. On the other hand, this database also offers an
advantage to clinicians in neurology practice who may not be
familiar with the ACDs in combination chemotherapy regimens. In
such cases, clinicians can search based on the acronym of the
regimen, and even narrow their regimen searches based on the
type of cancer treated, and OncoRx will be able to provide the
clinicianwith any identiﬁed drug interactionswith the drugs in the
regimen.
Another feature is the inclusion of a feedback form which seeks
users’ comments on how the OncoRx database can be improved.
This form serves as an important component for OncoRx as it
would determine the usefulness of this database in clinical
practice, and also its target audience. The feedback obtained will
then allow us to constantly update the database with features and
DDI information that are clinically relevant to practicing clinicians.
4. Discussion
4.1. Translating bench to bedside with cancer informatics—OncoRx
is the bridge
Translational research has been an area of discussionwithin the
scientiﬁc community in recent years. The Translational Research
Working Group (TRWG) at the National Cancer Institute (NCI)
relates translational research to scientiﬁc discoveries from
laboratory, clinical or population studies which lead to clinical
applications that can reduce cancer incidence, morbidity and
mortality.33 However, it is more commonly understood as the
application of science that ‘‘translates’’ discoveries from the
laboratory bench to the patient’s bedside or frommouse to man.34
The integration of healthcare with informatics and interactive
technologies has enabled computational tools to play an important
Fig. 3. Screenshots of the interaction search between doxorubicin and valproic acid. (a) Users select the anticancer (ACD) and antiepileptic drugs (AED) from the scroll-down
menu and pull-down list. (b) Results of the search, showing the pharmacokinetics of the ACD and AED, as well as the parameters of the detected interaction.
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particularly in oncology. However, there is a further need to link
basic biomolecular research to the clinical sciences with more
effective informatics and protocol management. Medical infor-
matics is a basic biomedical science that draws on both the
informatics and health services arenas to develop studies and
instruments to solve clinical issues in the practical setting.35
Inherently, medical informatics has twomain objectives: to search
for new knowledge, and to utilize this knowledge in application
research so as to improve healthcare practice.36Cancer informatics is a branch of medical informatics which
applies informatics, internet and interactive technologies to the
oncology domain; and can provide a bidirectional interplay
between laboratory research and clinical practice.37 Data on
new anticancer agents (e.g. targeted therapies) and combination
regimens ﬂow from academic and industrial research to the
clinical setting for therapeutic management of the disease, while
patient-oriented research provides ideas and biological data for the
laboratory to search for newer targets for drug discovery and
development. The development of OncoRx can be visualized as a
Fig. 4. Screenshots of the interaction search between the combination chemotherapy regimen EP and phenytoin. (a) Users select the chemotherapy regimen and antiepileptic
drug from the scroll-downmenu and pull-down list. (b) Results of the search, showing information about the regimen, interaction data of each anticancer drug in the regimen,
and an overall proposed management plan for the interaction with the regimen.
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animal models (bench) to clinical practice (bedside). Pharmaceu-
tical care in cancer patients can be improved through the use of this
database, since it can potentially minimize the occurrence of drug-
related problems such as drug interactions.
4.2. Antiepileptic drugs as the ﬁrst module in OncoRx
Drug interactions due to AEDs are extremely common in clinical
practice. An estimated 6% of patientswith AED intoxication are dueto drug interactions.38 This is because the probability of a co-
prescription in patients onAED therapy is high since AEDs are often
administered chronically, possibly over a lifetime. Patientswho are
treated with certain types of anticancer agents, for example
busulfan,39 are prone to generalized seizures and seizure
prophylaxes are often warranted in these patients.39,40 High-dose
busulfan may lead to neurotoxicity in the patient since it crosses
the blood–brain barrier rapidly with a cerebrospinal ﬂuid to
plasma ratio of 1:1,40 and it is estimated that the occurrence of
seizures in adults and children on high-dose busulfan is 10% and
Fig. 5. Chemotherapy regimens in OncoRx listed according to the types of cancers they treat.
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anticonvulsant used for this purpose, but it is associated with
altering the pharmacokinetics, and possibly the pharmacodynam-
ics, of busulfan as well.41 Thus, the ﬁrst module of OncoRx focused
on DDIs of ACDs and combination chemotherapy regimens with
anticonvulsants, which in essence, limits the database to only
being able to detect interactionswith 1 class of psychotropic drugs.
However, this was done so as to cater towards clinicians who
prescribe this class of drugs, so that they can treat the patientmore
effectively by avoiding inadequate drug levels or potential dose-
related toxicities.
4.3. Potential of the OncoRx database in clinical practice
Currently, there is no oncology-speciﬁc database which allows
healthcare professionals to search for interactions by both
individual ACDs and combination chemotherapy regimens. Al-
though some databases such as OncoLink,42 Adjuvant Online,43
and the BC Cancer Agency (BCCA) cancer drug manual26 provide
useful information on ACDs and cancer therapies, they do not
speciﬁcally target chemotherapy drug interactions. OncoRx caters
towards a niche group of healthcare professionals working in the
clinical oncology or neurology setting, who may deal with cancer
patients on chemotherapy in their daily practice. The main
advantage of OncoRx is its ease of use for practitioners to search
for chemotherapy drug interactions ‘‘on-the-spot’’, as and when
they encounter them. As far as we know, there is currently no drug
interaction database which allows users to search for drug
interactions via combination chemotherapy regimens. OncoRx is
the ﬁrst database of its kind which targets the DDIs of
chemotherapy regimens. This database saves time and effort on
the part of healthcare professionals as they do not need to searchfor interactions of the individual drugs in a combination regimen
(since they are standard within the regimen), but rather through
their acronyms. Furthermore, OncoRx provides a proposed plan for
managing the combination chemotherapy regimen if a drug
interaction is detected. This makes it easier for the management of
the patient since the healthcare professional can get the overall
view of the interactions in the regimen, instead of collating and
extracting relevant information for each individual drug interac-
tion himself.
The content in the OncoRx database is summarized and placed
under relevant headings so that the health professional can rapidly
sieve out the relevant information they need. Although several
drug information databases provide detailed information about an
interaction, it is a time consuming process for the clinician since it
requires a thorough read of the details in order to sieve out the
relevant information in the practice setting. On the other hand,
other databases only provide a summarized paragraph of the
detected drug interaction, mainly on the interaction effects and
precautions to take. Users may have to search other information
resources for more details on the interactions.
Some resources do not provide interactions of individual drugs,
but of drug classes or drugs with certain common parameters
instead. This requires some specialized knowledge on the part of
the healthcare professional regarding the drug, and may be time
consuming if he needs to look up additional information in the
practice setting. For example, the increased risk of carboplatin
toxicity when used concomitantly with nephrotoxic drugs24
implies that the clinician needs to know whether the interacting
drug is nephrotoxic, or otherwise look up for this piece of
information on the interacting drug. OncoRx enables its users to
search for interactions between speciﬁc drug-pairs, since it
extrapolates these class effects to the individual drugs.
Fig. 6. Screenshots of the interaction results between dexamethasone and phenytoin. A summary of evidences describing the inconsistency in the interaction effect of
dexamethasone on plasma phenytoin levels is provided together with substantiating references to clinicians.
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various drug information and interactions sources, as well as other
published literature. This makes the database a comprehensive
one. As a result, OncoRx is also able to provide the clinician with
any contradictory information regarding a detected drug interac-
tion. For example, corticosteroids such as dexamethasone which
are commonly used as antiemetic agents in treating chemothera-
py-induced nausea and vomiting,44 have been reported to cause
both increases and decreases in plasma phenytoin levels. The
OncoRx database is able to provide this piece of information as a
summary of the evidencewith substantiating references (Fig. 6), so
that the healthcare professional has the ﬂexibility of deciding how
to manage the patient based on his clinical judgment.
4.4. Limitations and future work
The main limitation of OncoRx is that it is currently only able to
provide DDI information between ACDs and AEDs. However, the
interaction data in our database is compiled in modular format,
and further modules on DDIs with other psychotropic drugs and
agents which have high potential of manifesting interactions with
ACDs will be considered. OncoRx is also currently limited to
searching for only one interaction at any one time. Separate
searches have to be carried out when detecting more than one
interaction and this can be troublesome for the user. Improve-
ments in the search interface will also be considered as more
modules are being added to the database. Moreover, with the
advent of mobile handheld devices, the potential of incorporating
our database into personal digital assistants (PDAs) is alsoattractive. OncoRx is intended to be updated regularly on an
annual basis so that the DDI-related information regarding ACDs
and chemotherapy regimens will remain current.
5. Conclusions
OncoRx is an oncology drug interaction database which allows
the identiﬁcation of DDIs between anticancer agents and adjuvant
drug therapy, and can be accessed at the website www.onco-
informatics.com. This database was developed as part of a doctoral
research project by a registered pharmacist in Singapore dual-
trained in the pharmaceutical sciences and in digital media
creation; in consultation with professors at the Department of
Pharmacy, Faculty of Science, National University of Singapore; of
whom one of them is US board-certiﬁed as both a pharmacother-
apy specialist and an oncology pharmacist, with a concurrent
appointment at the pharmacy department in the National Cancer
Center, Singapore. OncoRx is the ﬁrst database of its kind to be able
to detect interactions for combination chemotherapy regimens.
This database comprises relevant information related to the
pharmacokinetic properties of the anticancer agents, as well as
the drug interactions with other medications, such as antic-
onvulsants. OncoRx is meant to complement the currently
available drug databases used by clinicians to improve the
pharmaceutical care of cancer patients. By increasing the
awareness of oncology drug interactions among healthcare
professionals and other researchers in this ﬁeld, we hope that
our database will provide the bridge in cancer informatics to bring
oncology drug interactions from bench to bedside.
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